Nanogea has demonstrated the feasibility of using an antibody linked to a NanoConeTM coated AFM tip to detect PSA antigens at the molecular level. Moreover, Nanogea can directly detect and quantify PSA in blood (plasma) sample without sample preparation and any amplification step. The same approach can be used for detection and monitoring of many other diseases.
Hepatitis C (HCV) Test for Diagnosis and Treatment Monitoring. Hepatitis C is caused by HCV infection that affects the liver. It is estimated that 3.9 million Americans are infected with HCV. Of these 2.7 million suffer from chronic Hepatitis C most of whom need ongoing monitoring. World-wide, there are 170 million cases.
Nanogea has started working with a leading U.S. diagnostic company to develop HCV NE-AFMTM based tests for HCV Antibody test, HCV Viral load test, HCV Genotype test.
HCG-Ultra Test. Human Chorionic Gonadotropin or HCG is produced by the embryo after in vitro fertilization (IVF). Ultra-sensitive HCG test (<0.001 mIU/ml) can help a physician determine the heath status of an embryo before implantation, resulting in higher chance of giving healthy babies, fewer unwanted multiple births, and significant cost saving. Infertility affects 7.3 million women in U.S. alone. It is estimated that each year there are more than 500,000 IVF cycles performed per year.
Nanogea has partnered with several leading experts to develop early HCG tests to assist Infertility Treatment by IVF.
Alzheimer's Disease. Alzheimer's is a progressive brain disease. Approximately 5.3 million Americans are living with the disease. Alzheimer's destroys brain cells, causing memory loss and problems with thinking and behavior severe enough to affect work, lifelong hobbies or social life. Today the disease is the seventh-leading cause of death in the United States.
Nanogea is exploring methods for early detection of Alzheimer's Disease with Dr. Thomas Caskey and key members of the Brown Foundation Institute.